Screener
MBX Biosciences, Inc. MBX Total Operating Expenses
Total Operating Expenses at other companies
Other financials
Where this comes from
Reported directly by MBX Biosciences, Inc. in its filing.
Tagged under the XBRL concept us-gaap:OperatingExpenses.
The source filing: MBX Biosciences, Inc.’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 9:03 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-210593
| Line item | Three months ended March 31, 2026 | Three months ended March 31, 2025 |
|---|---|---|
| Operating expenses | ||
| Research and development | $18,474 | $22,405 |
| General and administrative | 8,791 | 4,124 |
| Total operating expenses | 27,265 | 26,529 |
| Loss from operations | (27,265) | (26,529) |
| Interest and other income, net | 3,748 | 2,649 |
| Net loss | $(23,517) | $(23,880) |
| Unrealized loss on marketable securities | (892) | (2) |
Item 1. Financial Statements.
FAQ
- What is MBX Biosciences, Inc.'s total operating expenses?
- MBX Biosciences, Inc. (MBX) reported total operating expenses of $27.27M in Q1 2026.
- How has MBX Biosciences, Inc.'s total operating expenses changed year-over-year?
- MBX Biosciences, Inc.'s total operating expenses increased by 2.8% year-over-year, from $26.53M to $27.27M.
- What does total operating expenses mean?
- The sum of all operating costs including COGS, SG&A, R&D, D&A, and other operating charges. Revenue minus total operating expenses equals operating income.
Ask your AI about MBX Biosciences, Inc.'s total operating expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude